Section Arrow
IONS.NASDAQ
- Ionis Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/15 09:41 EDT
Regular Hours
Last
 76.39
-0.37 (-0.48%)
Day High 
77.18 
Prev. Close
76.76 
1-M High
77.375 
Volume 
19.49K 
Bid
76.04
Ask
76.77
Day Low
76.3 
Open
77.1 
1-M Low
68.9 
Market Cap 
12.68B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 75.15 
20-SMA 73.5 
50-SMA 77.64 
52-W High 86.74 
52-W Low 27.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.38/-0.71
Enterprise Value
14.29B
Balance Sheet
Book Value Per Share
2.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
705.14M
Operating Revenue Per Share
3.72
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.8799+0.5651+179.51%-- 
LIMNLiminatus Pharma Inc0.196+0.0162+9.01%-- 
ALLOAllogene Therapeutics1.885-0.395-17.32%-- 
LNAILunai Bioworks Inc.0.2984-0.0404-11.92%-- 
RVMDRevolution Medicines149.035+2.025+1.38%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.